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Simple microneedle devices for delivery of drugs across or 
into biological tissue are provided, which permit drug deliv-
ery at clinically relevant rates across or into skin or other 
tissue barriers, with minimal or no damage, pain, or irritation 
to the tissue. The devices include a substrate to which a 
plurality of hollow microneedles are attached or integrated, 
and at least one reservoir, containing the drug, selectably in 
communication with the microneedles, wherein the volume 
or amount of drug to be delivered can be selectively altered. 
The reservoir can be formed of a deformable, preferably 
elastic, material. The device typically includes a means, such 
as a plunger, for compressing the reservoir to drive the drug 
from the reservoir through the microneedles. In one embodi-
ment, the reservoir is a syringe or pump connected to the 
substrate. 
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MICRONEEDLE DRUG DELIVERY DEVICE 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
2 
microneedles. The means can include a plunger or osmotic 
pump. In one embodiment, the reservoir is a syringe or pump 
connected to the substrate. 
The device also can include a sealing mechanism to 
contain the drug in one or more of the reservoirs until it is 
ready to be delivered or mixed with a liquid carrier. In one 
embodiment, the sealing mechanism is a fracturable barrier 
interposed between the reservoir and the substrate. 
This application is a continuation of U.S. Ser. No. 09/452, 
979, now U.S. Pat. No. 6,611,707, filed Dec. 2, 1999, which 
claims priority to U.S. provisional application Ser. No. 
60/137,621, filed Jun. 4, 1999, the specifications of which 
are incorporated by reference herein in their entireties. 
BACKGROUND OF THE INVENTION 
In one embodiment, the device includes a means for 
10 providing feedback to the user to indicate that delivery has 
been initiated and/or completed. An example of the feedback 
means is a color change. 
A common technique for delivering drugs across or into 
biological tissue is the use of a needle, such as those used 15 
with standard syringes or catheters, to transport drugs across 
(through) the skin. While effective for this purpose, needles 
generally cause pain; local damage to the skin at the site of 
insertion; bleeding, which increases the risk of disease 
transmission; and a wound sufficiently large to be a site of 20 
infection. Needle techniques also generally require admin-
istration by one trained in its use. The needle technique also 
is undesirable for long term, controlled continuous drug 
delivery. 
An alternative delivery technique is the transdermal 25 
patch, which usually relies on diffusion of the drug across 
the skin. However, this method is not useful for many drugs, 
due to the poor permeability (i.e. effective barrier properties) 
of the skin. The rate of diffusion depends in part on the size 
and hydrophilicity of the drug molecules and the concen- 30 
tration gradient across the stratum comeum. Few drugs have 
the necessary physiochemical properties to be effectively 
delivered through the skin by passive diffusion. Iontophore-
sis, electroporation, ultrasound, and heat (so-called active 
systems) have been used in an attempt to improve the rate of 35 
delivery. While providing varying degrees of enhancement, 
these techniques are not suitable for all types of drugs, 
failing to provide the desired level of delivery. In some 
cases, they are also painful and inconvenient or impractical 
for continuous controlled drug delivery over a period of 40 
hours or days. 
Attempts have been made to design alternative devices for 
active transfer of drugs, but there remains a need for better 
drug delivery devices, which make smaller incisions, deliver 
drug with greater efficiency (greater drug delivery per quan- 45 
tity applied) and less variability of drug administration, 
and/or are easier to use. 
It is therefore an object of the present invention to provide 
a microneedle device for relatively painless, controlled, safe, 
convenient transdermal delivery of a variety of drugs. 
SUMMARY OF THE INVENTION 
50 
In another embodiment, the microneedle device further 
includes a rate control means, such as a semi-permeable 
membrane, to regulate the rate or extent of drug which flows 
through the microneedles. 
The microneedle devices preferably are provided with 
means for preventing undesired reuse of or contact with the 
microneedles. These means can include protective packag-
ing, such as a peelable liner that temporarily covers the tips 
of the microneedles. The packaging also can be used to shear 
off the microneedles following their intended use, thereby 
preventing their reuse. 
BRIEF DESCRIPTION OF THE FIGURES 
FIGS. la-c are cross-sectional views of preferred 
embodiments of a microneedle drug delivery device. The 
device of FIG. la includes a reservoir and is suitable for 
transdermal drug delivery. The device of FIGS. la and lb 
includes a deformable reservoir, wherein delivery is acti-
vated by manual, e.g., finger or thumb, pressure applied to 
compress the reservoir directly (lb) or indirectly (le). 
FIG. 2 is a cross-sectional view of another preferred 
embodiment of a microneedle drug delivery device, wherein 
delivery is activated by manual pressure applied via a 
plunger to compress the reservoir. 
FIG. 3 is a cross-sectional view of another preferred 
embodiment of a microneedle drug delivery device, wherein 
delivery is activated by releasing a compressed spring which 
forces the plunger to compress the reservoir. 
FIGS. 4a-b are cross-sectional views of preferred 
embodiments of a microneedle drug delivery device having 
a multiple chambered reservoirs. 
FIG. 5 is a cross-sectional view of a preferred embodi-
ment of the microneedle drug delivery device, which incor-
porates an osmotic pump to force the drug contents from the 
reserv01r. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The microneedle devices include at least three compo-
nents: at least one, more preferably more, microneedle(s); a Simple microneedle devices are provided for delivery of 
drugs across or into biological tissue, particularly the skin. 
The microneedle devices permit drug delivery at clinically 
relevant rates across or into skin or other tissue barriers, with 
minimal or no damage, pain, or irritation to the tissue. 
The devices include a plurality of hollow microneedles, 
which are attached to or integrated into a substrate, and at 
least one reservoir selectably in communication with the 
microneedles, wherein the volume or amount of drug to be 
delivered can be selectively altered. The reservoir contains 
the drug to be delivered. In one embodiment, the reservoir 
is formed of a deformable, preferably elastic, material. 
55 substrate to which the base of the microneedle(s) are secured 
or integrated; and at least one reservoir that is selectably in 
fluid connection with one or more of the microneedles. 
Preferably, the microneedles are provided as a multi-dimen-
sional array, in contrast to a device with a single microneedle 
The device also can include means for compressing the 
reservoir to drive the drug from the reservoir through the 
60 or single row of microneedles. The microneedle device can 
be adapted to be a single-use, disposable device, or can be 
adapted to be fully or partially reusable. 
Microneedles 
The microneedles are hollow; that is, each contains at 
65 least one substantially annular bore or channel having a 
diameter large enough to permit passage of a drug-contain-
ing fluid and/or solid materials through the microneedle. The 
US 7,226,439 B2 
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hollow shafts may be linear, i.e. extend upwardly from 
needle base to needle tip, or they may take a more complex 
path, e.g. extend upwardly from the needle base, but then 
lead to one or more 'portholes' or 'slits' on the sides of the 
needles, rather than an opening at the needle tip. 
4 
The microneedles can be constructed from a variety of 
materials, including metals, ceramics, semiconductors, 
organics, polymers, and composites. Preferred materials of 
construction include pharmaceutical grade stainless steel, 
gold, titanium, nickel, iron, tin, chromium, copper, palla-
dium, platinum, alloys of these or other metals, silicon, 
silicon dioxide, and polymers. Representative biodegradable 
polymers include polymers of hydroxy acids such as lactic 
acid and glycolic acid polylactide, polyglycolide, polylac-
tide-co-glycolide, and copolymers with PEG, polyanhy-
drides, poly( ortho )esters, polyurethanes, poly(butyric acid), 
poly(valeric acid), and poly(lactide-co-caprolactone). Rep-
resentative non-biodegradable polymers include polycar-
bonate, polyester, and polyacrylamides. 
The length of the microneedles typically is between about 
10 µm and 1 mm, preferably between 100 µm and 500 µm, 
and more preferably between 150 µm and 350 µm. The 
length is selected for the particular application, accounting 
for both an inserted and uninserted portion. An array of 
microneedles can include a mixture of microneedles having, 
for example, various lengths, outer diameters, inner diam-
eters, cross-sectional shapes, and spacings between the 
microneedles. In transdermal applications, the "insertion 
10 depth" of the microneedles is preferably less than about 
100-150 µm, so that insertion of the microneedles into the 
skin does not penetrate into the dermis, thereby avoiding 
contacting nerves which may cause pain. In such applica-
15 tions, the actual length of the microneedles typically is 
longer, since the portion of the microneedles distal the tip 
may not be inserted into the skin; the uninserted length 
depends on the particular device design and configuration. 
The actual (overall) height or length of microneedles should 
20 be equal to the insertion depth plus the uninserted length. The microneedles should have the mechanical strength to 
remain intact while being inserted into the biological barrier, 
while remaining in place for up to a number of days, and 
while being removed. In embodiments where the micron-
eedles are formed of biodegradable polymers, the micron-
eedle must to remain intact at least long enough for the 25 
microneedle to serve its intended purpose (e.g., its conduit 
function for delivery of drug). The microneedles should be 
sterilizable using standard methods such as ethylene oxide 
or gamma irradiation. 
The microneedles can have straight or tapered shafts. In 30 
a preferred embodiment, the diameter of the microneedle is 
greatest at the base end of the microneedle and tapers to a 
point at the end distal the base. The microneedle can also be 
fabricated to have a shaft that includes both a straight 
(untapered) portion and a tapered portion. The needles may 35 
also not have a tapered end at all, i.e. they may simply be 
cylinders with blunt or flat tips. A hollow microneedle that 
has a substantially uniform diameter, but which does not 
taper to a point, is referred to herein as a "microtube." As 
used herein, the term "microneedle" includes both micro- 40 
tubes and tapered needles unless otherwise indicated. 
The microneedles can be oriented perpendicular or at an 
angle to the substrate. Preferably, the microneedles are 
oriented perpendicular to the substrate so that a larger 
density of microneedles per unit area of substrate can be 45 
provided. An array of microneedles can include a mixture of 
microneedle orientations, heights, or other parameters. 
Substrate 
The substrate of the device can be constructed from a 
variety of materials, including metals, ceramics, semicon-
ductors, organics, polymers, and composites. The substrate 
includes the base to which the microneedles are attached or 
integrally formed. The substrate can be adapted to fit a 
Luer-Lock syringe or other conventionally used drug deliv-
ery device that currently uses hypodermic needles as the 
barrier penetration method. 
In one embodiment of the device, the substrate, as well as 
other components, are formed from flexible materials to 
allow the device to fit the contours of the biological barrier, 
such as the skin, vessel walls, or the eye, to which the device 
is applied. A flexible device may facilitate more consistent 
penetration of some biological barriers, because penetration 
can be limited by deviations in the attachment surface. For 
example, the surface of human skin is not flat due to 
dermatoglyphics (i.e. tiny wrinkles) and hair. However, for 
some biological barriers, a rigid substrate may be preferred. 
Reservoir 
The reservoir is selectably in connection with the micron-
eedle bore, such that the reservoir contents can flow from the 
reservoir and out through the microneedle tip, into the target 
tissue. Typically, it is attached to, or integrated into, the 
substrate, either integrally (as in a one-piece device) or at the 
moment of drug delivery (as with a Luer-lock type device). 
The reservoir is to provide suitable, leak-free storage of the 
drug composition before it is to be delivered. The reservoir 
The microneedles can be formed with shafts that have a 
circular cross-section in the perpendicular, or the cross-
section can be non-circular. For example, the cross-section 
of the microneedle can be polygonal (e.g. star-shaped, 
square, triangular), oblong, or another shape. The shaft can 
have one or more bores. The cross-sectional dimensions 
typically are between about 1 µm and 500 µm, and prefer-
ably between 10 and 100 µm. The outer diameter is typically 
between about 10 µm and about 100 µm, and the inner 
diameter is typically between about 3 µm and about 80 µm. 
50 should keep the drug composition free of contaminants and 
degradation-enhancing agents. For example, the reservoir 
should exclude light when the drug composition contains 
photo-sensitive materials, and should include an oxygen 
barrier material in order to minimize exposure of drugs 
55 sensitive to oxidation. Also, the reservoir should keep vola-
tile materials inside the reservoir, for example, to prevent 
water from evaporating, causing the drug composition to dry 
out and become undeliverable. In one embodiment the cross-sectional dimensions are 
designed to leave a residual hole (following microneedle 
insertion and withdrawal) ofless than about 0.2 µm, to avoid 
making a hole which would allow bacteria to enter the 
penetration wound. The actual microneedle diameter will 
typically be in the few micron range, since the holes 
typically contract following withdrawal of the microneedle. 
Larger diameter and longer microneedles are acceptable, so 65 
long as the microneedle can penetrate the biological barrier 
to the desired depth. 
The drug reservoir can be substantially rigid or readily 
60 deformable. The reservoir can be formed from one or more 
polymers, metals, ceramics, or combinations thereof. In a 
preferred embodiment, the reservoir includes a volume 
surrounded by one or more walls, or includes a porous 
material, such as a sponge, which can retain, for example, 
the drug liquid until the material is compressed. 
In a preferred embodiment, the reservoir is formed of an 
elastic material, such as an elastomeric polymer or rubber. 
US 7,226,439 B2 
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For example, the reservoir can be a balloon-like pouch that 
is stretched (in tension) when filled with a fluid drug 
composition to be delivered. 
The reservoir of a single microneedle device can include 
a plurality of compartments that are isolated from one 
another and/or from a portion of the microneedles in an 
array. The device can, for example, be provided to deliver 
different drugs through different needles, or to deliver the 
same or different drugs at different rates or at different times 
(FIG. 4a ). Alternatively, the contents of the different com- 10 
partments can be combined with one another, for example, 
by piercing, or otherwise removing, a barrier between the 
compartments, so as to allow the materials to mix. In a 
preferred embodiment, one compartment contains a saline 
solution or another delivery vehicle, while another compart- 15 
ment contains lyophilized drug (FIG. 4b). In a preferred 
embodiment, the reservoir is a standard or Luer-Lock 
syringe adapted to connect to a microneedle array. 
Methods for Manufacture of the Devices 
6 
secured to the upper surface of substrate 12 by plunger guide 
frame 24 using a restraint such as a Luer-lock interface 23. 
The substrate 12 can be attached or detached to a syringe 26 
via a connector such as a Luer-lock type attachment 23. The 
plunger 22, guide frame 24, and connector 23 connect to, 
form or contain reservoir 16. A Luer-lock type attachment 
could alternatively be used to secure the device to means for 
controlling flow or transport through the device such as a 
pump. 
A further preferred embodiment of the microneedle 
device is shown in FIG. 3. Like the device in FIG. 2, the 
device 30 includes substrate 12, microneedles 14, plunger 
22, plunger guide frame 24, and reservoir 16. Device 30 
further includes plunger housing 32, which is attached to, or 
integrally formed with, plunger guide frame 24. A com-
pressed spring or other tension-based mechanism 34 is 
positioned between plunger housing 32 and plunger 22. The 
device 30 further includes spring hold/release mechanism 
36, which keeps the plunger up (spring compressed) until 
20 triggered to compress reservoir 16. The microneedle and substrate are made by methods 
known to those skilled in the art. Examples include micro-
fabrication processes, by creating small mechanical struc-
tures in silicon, metal, polymer, and other materials. Three-
dimensional arrays of hollow microneedles can be 
fabricated, for example, using combinations of dry etching 25 
processes; micromold creation in lithographically-defined 
polymers and selective sidewall electroplating; or direct 
micromolding techniques using epoxy mold transfers. These 
methods are described, for example, in U.S. Ser. No. 091095, 
221, filed Jun. 10, 1998; U.S. Ser. No. 09/316,229, filed May 30 
21, 1999; Henry, et al., "Micromachined Needles for the 
Transdermal Delivery of Drugs," Micro Electro Mechanical 
Systems, Heidelberg, Germany, pp. 494-98 (Jan. 26-29, 
1998). 
EXAMPLES 
Preferred embodiments of the microneedle device are 
shown in FIGS. la--c. The device 10 includes substrate 12 
from which a three-dimensional array of microneedles 14 
protrude. As shown, the annular bore of the microneedles 14 
extends through the substrate 12. The device 10 also 
includes a reservoir 16 secured to substrate 12 via a sealing 
mechanism 18. FIG. la shows how the reservoir can be 
Attachment Feature 
In a preferred embodiment, the microneedle device 
includes an adhesive material to secure the microneedle 
device to the skin, temporarily immobilizing the micron-
eedles while inserted into the skin to deliver the drug. The 
adhesive agent typically is applied to the substrate (in 
between the microneedles at their base) or to an attachment 
collar or tabs adjacent the microneedles. 
Care must be taken so that any adhesive agent does not 
plug the bores of hollow microneedles. For example, the 
adhesive agent can be applied in a liquid solution by 
flooding the top of the substrate below the tips of the 
microneedles, such as from the side of an array of micron-
eedles, or by using a three-dimensional printing process. The 
35 
solvent can then be evaporated from the adhesive agent 
solution, thereby precipitating or gelling the adhesive agent 
to yield a tacky surface. An alternate method of keeping the 
tips free of an applied adhesive agent is to choose materials 
of construction having a hydrophobicity or hydrophilicity to 
40 
control the wetting of the surface to the microneedle tips. 
Initiating Delivery 
accessed directly by application to the skin, for example, for 45 
simple transdermal delivery of an agent. The device in FIG. 
In a preferred embodiment, delivery of the drug from the 
reservoir is initiated by applying a force, such as by pressing 
the top of the reservoir, to cause the reservoir contents (i.e. 
a drug containing composition) to flow out through the 
microneedles-an active or dynamic process. For example, 
the user can apply finger-pressure directly to a deformable 
reservoir "bubble," (FIG. 1) or to a plunger mechanism 
lb includes a deformable bubble reservoir 16. Manual 
pressure can be used to expel its contents at the site of 
application. FIG. le shows a separate reservoir 16 from 
means 19 for expelling the contents of the reservoir 16 at the 
site of administration. The expelling means 19 can be simply 
a flexible bag. The expelling means 19 may also contain a 
vacuum so that it expands when vented, to create pressure on 
the reservoir, or it may be elastic so that it deforms when 
released from one position (not shown). Alternatively, res-
ervoir 16 could be formed of an elastic material which 
50 (FIG. 2) or a Luer-lock type syringe that in tum causes the 
drug composition to be forced from the reservoir. The 
plunger also can be adapted to activate by application of a 
constant, reproducible force, for example, a spring (e.g., 
under compression) (FIG. 3) or elastic band (e.g., in ten-
55 sion). 
A variation of this embodiment utilizes a balloon-like 
deforms when released. reservoir in tension to provide the force. Then, when an 
The sealing mechanism 18 can be, for example, an opening is formed in the balloon reservoir, the contents are 
adhesive material or gasket. The sealing mechanism 18 can forced out of the reservoir as the balloon contracts to its 
further function as or include a fracturable barrier or rate 60 relaxed state. The contraction is selectively triggered to 
controlling membrane overlaying the surface of the sub- provide the driving force for delivery. 
strate. In this embodiment, nothing can be released until a In a preferred embodiment, the force ruptures a fractur-
seal or peel-off strip covering is removed. able barrier between the reservoir contents and the inlet of 
Another preferred embodiment of the microneedle device the microneedle. Representative barriers include thin foil, 
is shown in FIG. 2. The device 20 includes substrate 12 from 65 polymer, or laminant films. In another preferred embodi-
which a three-dimensional array of microneedles 14 pro- ment, the microneedles tips are blocked until immediately 
trude. The device 20 also includes plunger 22 that is slidably before use. The blocking material can be, for example, a 
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peelable adhesive or gel film, which will not clog the 
openings in the microneedle tip when the film is removed 
from the device. 
Delivery also can be initiated by opening a mechanical 
gate or valve interposed between the reservoir outlet and the 
microneedle inlet. For example, a thin film or plate can be 
slid or peeled away from the back of the substrate. 
In an alternate embodiment, delivery is initiated by 
changing the physical or chemical properties of the drug 
composition and/or of a barrier material. For example, the 10 
barrier can be a porous membrane having a porosity that can 
be selectably altered to permit flow, or the drug composition 
can be selected to change from a solid or semi-solid state to 
a fluid state, for example as the temperature is increased 
from ambient to that of body temperature. Such a drug 15 
composition can be prepared, for example, by combining the 
drug with a biodegradable polymeric material. 
8 
reservoir 68. Using this device 60, water can be drawn from 
the reservoir 68 across the semi-permeable membrane 70 
into the reservoir 66 due to osmosis caused by the presence 
of salt in the reservoir 66. The flow of water will cause the 
volume of reservoir 66 to increase and thereby force the 
volume of reservoir 62 to decrease, which causes material to 
expel from reservoir 62 through microneedles 14. 
In an alternate embodiment, delivery is initiated by open-
ing the pathway between the reservoir and the microneedle 
tip, or unblocking the tip openings, and simply allowing the 
drug to be delivered by diffusion, that is, a passive process. 
Feedback About Delivery 
In a preferred embodiment, the microneedle device 
includes a feedback means so that the user can (1) determine 
whether delivery has been initiated; and/or (2) confirm that 
the reservoir has been emptied, that is delivery complete. 
Representative feedback means include a sound, a color 
(change) indicator, or a change in the shape of a deformable 
reservoir. In a preferred embodiment, the feedback for 
A preferred embodiment of the microneedle device is 
shown in FIG. 4a. FIG. 4a shows a device 40 in which 
microneedles 14 attached to a substrate 12 which is attached 
to multiple compartments l6a, l6b, 16c, and 16d. Each 
compartment can contain or function as a reservoir. Material 
can be expelled from each compartment through all or a 
subset of microneedles 14. 
20 completion of delivery is simply that the reservoir is pressed 
flat against the back of the substrate and cannot be further 
deformed. 
FIG. 4b depicts a device 50 in which microneedles 14 are 25 
attached to a substrate 12 which is attached to reservoir 58 
containing, for example, lyophilized drug 54. The reservoir 
58 is attached to a fracturable barrier 52 which is attached to 
another reservoir 56 containing, for example, saline. If the 
barrier 52 is fractured, then the two reservoirs 58 and 56 are 30 
in fluid communication with each other and their contents 
can mix. 
Delivery also can be initiated by activating an osmotic 
pump, as described, for example, in U.S. Pat. No. 4,320,758 
to Eckenhoff, which has been adapted to the substrate of the 35 
microneedle device. For example, the reservoir/osmotic 
pump includes an inner flexible bag that holds the drug 
charge, an intermediate layer of an osmotically effective 
solute composition, such as an inorganic salt, that encapsu-
lates the bag, and an outer shape-retaining membrane that is 40 
at least in part permeable to water and that encapsulates both 
the layer of osmotically effective solute composition and the 
bag. In operation, the bag filled with the fluid drug compo-
sitions is exposed to an aqueous environment, so that water 
Feedback About Penetration of the Microneedles into the 
Tissue 
The user of the microneedle device typically can Deter-
mine if the microneedles have been properly inserted into 
the skin or other tissue through visual or tactile means, that 
is assessing whether the substrate has been pressed essen-
tially flush to the tissue surface. For example, if a puddle of 
liquid drug composition appears near the device, then the 
user may infer that the microneedles are not fully inserted, 
suggesting that the device needs to be reapplied. The liquid 
drug compositions can include a coloring agent to enhance 
the visual feedback. 
In a more complex embodiment, an electrical or chemical 
measurement is adapted to provide the feedback. For 
example, penetration can be determined by measuring a 
change in electrical resistance at the skin or other tissue, or 
a pH change. Alternately, needle-to-needle electrical resis-
tance can be measured. In a preferred embodiment, the 
microneedle device includes a disposable cartridge contain-
ing the microneedles. In these devices, an LED (e.g. green 
light/red light) or liquid crystal display can be provided with 
the reusable portion of the device. 
Controlling the Delivery Rate 
The microneedle device must be capable of transporting 
drug across or into the tissue at a useful rate. For example, 
the microneedle device must be capable of delivering drug 
at a rate sufficient to be therapeutically useful. The rate of 
is imbibed from the environment by the osmotically effec- 45 
tive solute through the membrane into the space between the 
inner flexible bag and the membrane. Since the bag is 
flexible and the membrane is rigid, the imbibed water 
squeezes the bag inwardly, thereby displacing drug out the 
microneedles. 50 delivery of the drug composition can be controlled by 
altering one or more of several design variables. For 
example, the amount of material flowing through the needles 
can be controlled by manipulating the effective hydrody-
FIG. 5 shows a device 60 in which microneedles 14 are 
attached to a substrate 12 which is attached to a drug 
reservoir 62. This reservoir is surrounded at least partially by 
namic conductivity (the volumetric through-capacity) of a 
single device array, for example, by using more or fewer 
microneedles, by increasing or decreasing the number or 
diameter of the bores in the microneedles, or by filling at 
least some of the microneedle bores with a diffusion-limiting 
material. It is preferred, however, to simplify the manufac-
a flexible, impermeable membrane 64. The drug reservoir is 
connected to another reservoir 66 which contains, for 55 
example, an inorganic salt. The two reservoirs 62 and 66 are 
separated by the impermeable membrane 64, which is 
impermeable to the contents of both reservoirs 62 and 66. 
The reservoir 66 is also connected to another reservoir 68 
which contains, for example, an aqueous solution in which 
the organic salt is at least partially soluble. The two reser-
voirs 66 and 68 are separated by a rigid, semi-permeable 
membrane 70, which is partially or completely impermeable 
60 turing process by limiting the needle design to two or three 
"sizes" of microneedle arrays to accommodate, for example 
small, medium, and large volumetric flows, for which the 
delivery rate is controlled by other means. 
to the salt in reservoir 66 and partially or fully permeable to 
the solution in reservoir 68. There is also an optional fill port 
or vent 72 in communication with the reservoir 68, through 
which material can be added to or removed from the 
Other means for controlling the rate of delivery include 
65 varying the driving force applied to the drug composition in 
the reservoir. For example, in passive diffusion systems, the 
concentration of drug in the reservoir can be increased to 
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increase the rate of mass transfer. In active systems, for 
example, the pressure applied to the reservoir can be varied, 
such as by varying the spring constant or number of springs 
or elastic bands. 
In either active or passive systems, the barrier material 
can be selected to provide a particular rate of diffusion for 
the drug molecules being delivered through the barrier at the 
needle inlet. 
Drugs 
Essentially any drug can be delivered using the micron- 10 
eedle devices described herein. As used herein, the term 
"drug" refers to an agent which possesses therapeutic, 
prophylactic, or diagnostic properties in vivo, for example 
when administered to an animal, including mammals, such 
10 
removal can serve as a wipe to prepare the skin surface 
before insertion of the microneedles. 
The packaging also can be adapted to serve as a vessel for 
safely disposing of the used microneedle device. In a pre-
ferred embodiment, the single-use microneedles are pro-
vided a device or material to shear the needles from the 
substrate or plug the microneedles, so as to prevent unde-
sirable reuse of the device. In one embodiment, the inner 
back of the reservoir is provided with a tacky substance. 
When the reservoir is compressed against the back of the 
substrate following delivery of the reservoir contents, the 
tacky substance is driven into the opening of the micron-
eedles, plugging them. In one embodiment of this device, the 
tacky material dries and hardens so that the substance cannot 
readily be removed. 
Publications cited herein and the material for which they 
are cited are specifically incorporated by reference. Nothing 
herein is to be construed as an admission that the invention 
is not entitled to antedate such disclosure by virtue of prior 
as humans. Examples of suitable therapeutic and/or prophy- 15 
lactic active agents include proteins, such as hormones, 
antigens, and growth factors; nucleic acids, such as antisense 
molecules; and smaller molecules, such as antibiotics, ste-
roids, decongestants, neuroactive agents, anesthetics, and 
sedatives. Examples of suitable diagnostic agents include 
radioactive isotopes and radioopaque agents, metals, gases, 
labels including chromatographic, fluorescent or enzymatic 
labels. 
20 invention. 
Modifications and variations of the methods and devices 
described herein will be obvious to those skilled in the art 
from the foregoing detailed description. Such modifications 
and variations are intended to come within the scope of the 
25 appended claims. 
The drug can be or include a peptide, protein, carbohy-
drate (including monosaccharides, oligosaccharides, and 
polysaccharides), nucleoprotein, mucoprotein, lipoprotein, 
glycoprotein, nucleic acid molecules (including any form of 
DNA such as cDNA, RNA, or a fragment thereof, oligo-
nucleotides, and genes), nucleotide, nucleoside, lipid, bio-
logically active organic or inorganic molecules, or combi- 30 
nation thereof. 
The amount of drug can be selected by one of skill in the 
art, based, for example on the particular drug, the desired 
effect of the drug at the planned release levels, and the time 
span over which the drug should be released. 
Multi-Cartridge Microneedle Device 
A modification of the disposable, single use microneedle 
device utilizes a reusable triggering device (e.g., a plunger) 
35 
in combination with a cartridge containing one or more, 
preferably a plurality, of single-use microneedle devices. For 40 
example, the cartridge can be a circular disk having 10 or 12 
microneedle arrays connected to a single-dose reservoir, 
wherein the cartridge can be loaded into and unloaded from 
the triggering device. The triggering device can, for 
example, be designed to move a new dose into position for 45 
delivery, compress the reservoir to deliver the drug, and then 
eject or immobilize the used array. This type of reusable 
triggering device also can include a power source, such as a 
battery, used to operate a built-in measurement device, for 
example, for analyte measurement of interstitial fluids or 50 
electrical verification of needle penetration into skin, as 
described earlier in this document. 
Microneedle Device Packaging 
In a preferred embodiment following manufacture of the 
microneedle device, it is packaged for storage, shipment, 55 
and sale before use. The packaging should prevent contami-
nation and damage. The packaging also should prevent 
premature triggering or release of any drug or vehicle 
contents from the reservoir. 
It is particularly important that, the microneedle device is 60 
provided with a removable protective cover or cushion that 
protects the microneedles from damage. The protective 
cover also can function to keep the drug material from 
prematurely leaking out of the microneedles. In a preferred 
embodiment, an adhesive material or gel film used to 65 
selectively secure the cover over the microneedles. In an 
alternate embodiment, the film is antiseptic, and following 
We claim: 
1. A method for delivering an agent into a biological 
barrier, comprising providing a device having: 
a plurality of hollow microneedles having a base end and 
a tip, with at least one hollow pathway disposed 
between the base end and the tip, 
a substrate to which the base ends of the microneedles are 
attached, and 
at least one reservoir containing the agent to be delivered 
and being in fluidic connection with the base ends of at 
least one of the microneedles, 
selectively altering the volume of the reservoir, and 
inserting at least one of the microneedles into the bio-
logical barrier to deliver an agent through the micron-
eedles and into the biological barrier. 
2. The method of claim 1 further comprising reducing the 
volume of the agent in the reservoir by driving the agent 
through at least one of the microneedles. 
3. The method of claim 1 wherein the biological barrier is 
tissue. 
4. The method of claim 1 further comprising providing a 
reservoir formed of a material which is deformable. 
5. The method of claim 1 wherein the agent is selected 
from the group consisting of peptides, proteins, carbohy-
drates, nucleic acid molecules, lipids, organic molecules, 
biologically active inorganic molecules, and combinations 
thereof. 
6. The method of claim 1 further comprising providing a 
plunger for compressing the reservoir. 
7. The method of claim 1 further comprising employing 
an adhesive material for securing the device during delivery. 
8. The method of claim 1 further comprising adapting the 
substrate for removably connecting to a standard or Luer-
lock syringe. 
9. The method of claim 1 further comprising fracturing a 
barrier interposed between the reservoir and the substrate. 
10. The method of claim 1 further comprising monitoring 
feedback to indicate that delivery has been initiated or 
completed. 
11. The method of claim 1 further comprising mixing the 
agent with particles capable of blocking the hollow pathway 
and thereby preventing delivery of the agent. 
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12. The method of claim 1 further comprising providing 
an osmotic pump to move agent. 
13. The method of claim 1 comprising providing multiple 
reservmrs. 
14. The method of claim 13 wherein the reservoirs are in 
communication with each other. 
15. The method of claim 13 wherein one or more reser-
voirs contain a solid formulation and one or more reservoirs 
contains a liquid carrier for the solid formulation. 
16. The method of claim 1 further comprising regulating 10 
the rate at which the agent flows through the microneedles. 
12 
17. The method of claim 16 whereby regulating comprises 
disposing a membrane within the hollow pathway for con-
trolling the rate at which the agent follows through the 
hollow pathway. 
18. The method of claim 1 further comprising providing 
multiple microneedle arrays and means for accessing one or 
more arrays at a time. 
* * * * * 
